A randomized clinical trial published in JAMA Network Open found no significant overall benefit of maternal progesterone therapy on neurodevelopmental outcomes in infants with congenital heart defects, but observed improvements in female children and specific heart conditions.
Iovance’s PDUFA date for lifileucel pushed due to FDA backlog – Pharmaceutical Technology
The markets viewed the news favourably, as Iovance’s stock was up by over 15% in pre-market trading. Image Credit: Drozd Irina / Shutterstock. The US